"Find Global Investment Partners"... Bio Companies to Gather in San Francisco Next Week

The World's Largest Bio Investment Event 'JPM Healthcare Conference' Opens on the 13th
Leaders of Celltrion, Samsung, and Lotte Bio Present Business Achievements and Vision on Site

Heads of major domestic pharmaceutical and bio companies such as Celltrion, Samsung Biologics, and Lotte Biologics will simultaneously head to San Francisco, USA next week. They will attend the world's largest bio investment event, the 'J.P. Morgan Healthcare Conference (JPMHC),' held from the 13th to the 16th (local time), where they will lead efforts in attracting overseas investment, technology transfer, and external cooperation.

According to industry sources on the 9th, this year's 43rd JP Morgan Healthcare Conference is expected to host over 550 companies and more than 8,000 attendees. Held every January, this event provides insights into the latest research trends, business plans, and directions of bio investment from major global pharmaceutical companies including big pharma.

This year, the conference is expected to offer perspectives on healthcare policies under the second term of U.S. President Donald Trump's administration, as well as the direction of the Biosecure Act, Inflation Reduction Act (IRA), tariff policies in the bio and pharmaceutical industries, and the response strategies of major companies preparing for these changes.

Domestically, Samsung Biologics has been officially invited by JP Morgan for the ninth consecutive year and will present on the main track of the event. CEO John Rim will personally introduce this year's business plans, mid-to-long-term vision, and the background of the company's growth. Throughout the event, Samsung Biologics plans to focus on networking to expand its business by promoting its differentiated Contract Development and Manufacturing Organization (CDMO) competitiveness to investors and potential clients.

Celltrion will also have Chairman Seo Jung-jin and his eldest son, Seo Jin-seok, CEO of the Management Business Division, presenting on-site. They will share the development achievements of their current new drug pipeline and disclose the development schedule for a total of 13 new drug pipelines, including nine antibody-drug conjugate (ADC) new drugs and four multi-antibody new drugs planned through 2028. Celltrion is accelerating full-scale new drug development using new modalities based on the U.S. market-established drug 'Zimpentra.'

Bridge Biotherapeutics, selected for the first time as an on-site presenting company at the JP Morgan Healthcare Conference this year, will have CEO Lee Jung-kyu take the stage. CEO Lee plans to introduce the company's major R&D projects, including the idiopathic pulmonary fibrosis treatment candidate 'BBT-877,' and announce future corporate growth strategies. The company will also engage in negotiations for technology transfer agreements with numerous global companies.

At Lotte Biologics, newly appointed CEO James Park will introduce the construction status of the Songdo Bio Campus and the ADC production facility at the Syracuse Bio Campus in New York. Lotte Biologics is pushing forward with the establishment of three mega plants and a total of 360,000 liters of antibody drug production facilities by 2030, including completing the first plant of the Songdo Bio Campus with a 120,000-liter production capacity in the first quarter of next year.

Additionally, Oncogenic Therapeutics, which developed 'Jacubo,' the 37th domestic new drug and a P-CAB (potassium-competitive acid blocker) class treatment for gastroesophageal reflux disease, plans to hold meetings with global pharmaceutical companies and investors to introduce its new drug pipeline. While promoting the achievements of Jacubo, which has already been licensed out to 21 countries overseas, the company also aims for global expansion of its next-generation anticancer drug candidate 'Nesuparip.'

Last year, Hugel, whose botulinum toxin product 'Retivo' was approved in the U.S., will present its regional market entry status to global investors. Hugel has entered the three major global toxin markets?U.S., Europe, and China?and plans to expand its market further to the Middle East and North Africa.